NCT02967653View on ClinicalTrials.gov

Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions
Lithium Use, Nephrogenic Diabetes Insipidus
Interventions
DRUG

Atorvastatin

Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease

Trial Locations (3)

H3A1A1

McGill University Health Centre, Montreal

H3T1E4

Jewish General Hospital, Montreal

H4H1R3

Douglas Mental Health University Institute, Montreal

All Listed Sponsors
lead

Lady Davis Institute

OTHER

NCT02967653 - Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus | Biotech Hunter | Biotech Hunter